Mylan Inc. (MYL) confirmed that it was sued by Pfizer (PFE) in connection with the filing of an Abbreviated New Drug Application with the FDA for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 and 10/80 mg.
This product is the generic version of Caduet Tablets, which combine the long-acting calcium channel blocker amlodipine besylate with the synthetic lipid-lowering agent atorvastatin calcium, the company noted.
Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the 2.5/10 mg, 2.5/20 mg, 2.5/40 mg and 10/40 mg strengths and expects to qualify for 180 days of marketing exclusivity upon final FDA approval.
Caduet Tablets had approximately $65.6 million in sales for the 2.5/10 mg, 2.5/20 mg, 2.5/40 mg and 10/40 mg strengths for the twelve months ending Dec. 31, 2009, according to IMS Health.
For comments and feedback: editorial@rttnews.com